Research Reference
Selank
Tuftsin-derived peptide studied for anxiety and cognition
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
Selank is a tuftsin-derived peptide studied in Russia for anxiety and cognitive enhancement. It is not FDA approved.
Dosing Reference
Reconstitution
Add 5 mL bacteriostatic water to the 5 mg vial. Resulting concentration: 1 mg/mL.
| Dose | Syringe Units | mL Volume | Schedule |
|---|---|---|---|
| 250 mcg | 25 units | 0.25 mL | SubQ, 1–3x dailyCommunity anxiolytic protocol |
| 500 mcg | 50 units | 0.5 mL | SubQ, 1–3x dailyCommunity higher dose |
Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before use. Round half-units to the nearest visible mark.
Reconstitution
Selank is a synthetic heptapeptide developed in the Russian Federation and registered there as an anxiolytic. Compounded research-peptide forms are sold in 5 mg vials and are not FDA-approved in the United States.
For a 5 mg vial reconstituted with 5 mL bacteriostatic water, the concentration is 1 mg/mL; a 250 mcg dose draws to 25 units (0.25 mL) on a U-100 syringe. Gently swirl — do not shake — and store refrigerated. Compounded forms are not FDA-approved.
Cycling Protocol
Studied/community protocols describe Selank administered subcutaneously 1–3 times daily for 2–4 weeks, sometimes repeated. No standardized long-term cycle is established; Selank is not FDA-approved and durations are community extrapolation.
Routes of Administration
Subcutaneous injection: Administered into the abdomen or thigh with a 29–31 gauge insulin syringe, 1–3 times daily. Compounded forms are not FDA-approved.
Stacking Protocols
| Stack | Components | Purpose | | --- | --- | --- | | Anxiolytic Stack | Selank + Semax | Combined CIS-region nootropic/anxiolytic (community) | | Stress Stack | Selank + L-theanine / ashwagandha | Combined anxiolytic support (community) |
Stacking combinations are community extrapolation. Selank is not FDA-approved.
Side Effects & Safety
- Generally described as well-tolerated in the published CIS-region literature
- Nasal irritation — possible with intranasal use
- Sedation / fatigue — occasionally reported (paradoxical alertness also described)
- No large US safety database — the compound is not FDA-approved and Western safety data is limited
Selank is not FDA-approved in the United States. It is registered in some other countries. Compounded research-peptide forms are not FDA-approved.
Research Basis
Selank is a synthetic heptapeptide derived from the sequence of tuftsin (a natural immunomodulatory peptide), developed at the Institute of Molecular Genetics (Russian Federation).
Mechanism: Described as an anxiolytic and cognitive-support peptide that modulates brain-derived neurotrophic factor (BDNF), serotonin, and enkephalin metabolism without sedation or dependence.
Clinical evidence: Published CIS-region studies describe use in anxiety and stress-related conditions, typically as an intranasal spray. Not FDA-approved in the US; Western trial data is limited.
Not FDA-approved in the US. Compounded research-peptide forms are sold for research purposes only.